text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 50924-49-7 | Product Number: M2399

Mizoribine


Purity: >98.0%(HPLC)
Synonyms:
  • 1-(β-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide
Product Documents:
50MG
60,00 €
1   11  
250MG
207,00 €
1   8  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Supplemental Product Information:

This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.

Product Number M2399
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__9H__1__3N__3O__6 = 259.22 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
CAS RN 50924-49-7
Reaxys Registry Number 8155135
PubChem Substance ID 253659680
Merck Index (14) 6222
MDL Number

MFCD00057221

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Specific rotation [a]20/D -25.0 to -27.0 deg(C=2,H2O)
Properties (reference)
Melting Point 198 °C(dec.)
Specific Rotation -26° (C=2,H2O)
Maximum Absorption Wavelength 280 nm
GHS
Pictogram Pictogram Pictogram
Signal Word Danger
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H360 : May damage fertility or the unborn child.
H340 : May cause genetic defects.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
Related Laws:
RTECS# NI3980000
Transport Information:
HS Number 2940000080
Application
Mizoribine: An Imidazole Nucleoside Immunosuppressive and Antiviral Agent

Mizoribine (bredinin, MZR), an imidazole nucleoside, is an immunosuppressive and an antiviral agent. The immunosuppressive effect of mizoribine has been reported to be due to the inhibition of de novo guanosine synthesis, via inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH).1-4) On the other hand, the combination of mizoribine and interferon (IFN)-α have been reported to show antiviral activities. The mechanisms of action would appear that mizoribine inhibits virus RNA replication based on the depletion of the intracellular pool of guanosine nucleotides by IMPDH inhibition.5-7) In addition, mizoribine has been reported to its anti-coronavirus activity.8) (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Life Science
Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.